UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2014
__________________________________________
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
| Ontario, Canada | | 0-31198 | | Not Applicable |
| (State or other jurisdiction | | (Commission File Number) | | (I.R.S. Employer |
| of incorporation) | | | | Identification Number) |
151 Steeles Avenue East, Milton, Ontario, Canada
(Address of principal executive offices and zip code)
(519) 434-1540
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Regulation FD Disclosure
On August 6, 2014, Tribute Pharmaceuticals Canada Inc. (the Company) issued a press release announcing the Q2 2014 Results Discussion Conference Call. A copy of the Companys press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Currently you have this referencing to YE 2013.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| | |
| | 99.1 Tribute Pharmaceuticals Canada Inc. Press Release, dated August 6, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Tribute Pharmaceuticals Canada Inc. | |
| | | | |
| By: | /s/ Scott Langille | |
| | | Name: Scott Langille | |
| | | Title Chief Financial Officer | |
| | | | |
3
